Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North A ...